Compare Lumen Technologies Inc (LUMN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Lumen Technologies Inc trades at $6.76 (market cap $6.47B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Lumen Technologies Inc is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| LUMN | RXRX | |
|---|---|---|
Market Cap | $6.47B | $1.53B |
Sector | Media | Health |
52-Week High | $11.83 | $6.79 |
52-Week Low | $3.70 | $2.84 |
Enterprise Value | $18.10B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.76, up 7.64% today, but remains in a bearish technical trend with resistance at $7. The company reported a net loss of $1.74B in 2025 despite beating EPS estimates in two of the last three quarters. Recent news highlights AI-focused initiatives, including the acquisition of Alkira and recognition in Gartner's AI vendor report, signaling strategic repositioning amid declining revenue.
The outlook is cautious with high debt ($17.49B long-term) and negative profitability metrics posing significant risks. Analyst consensus is mixed (14% Buy, 61% Hold) with a $8.25 price target, suggesting limited upside. Investors should weigh cost-cutting progress and AI contract growth against persistent cash flow challenges and competitive pressures in telecom services.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
